News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
754,548 Results
Type
Article (45923)
Company Profile (333)
Press Release (708268)
Multimedia
Podcasts (152)
Webinars (25)
Section
Business (213052)
Career Advice (2206)
Deals (37276)
Drug Delivery (144)
Drug Development (84707)
Employer Resources (178)
FDA (17046)
Job Trends (15699)
News (361644)
Policy (34677)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2663)
Accelerated approval (43)
Adcomms (34)
Allergies (169)
Alliances (52228)
ALS (201)
Alzheimer's disease (1785)
Antibody-drug conjugate (ADC) (397)
Approvals (17335)
Artificial intelligence (634)
Autoimmune disease (233)
Automation (50)
Bankruptcy (379)
Best Places to Work (11841)
BIOSECURE Act (22)
Biosimilars (214)
Biotechnology (194)
Bladder cancer (178)
Brain cancer (67)
Breast cancer (702)
Cancer (5458)
Cardiovascular disease (479)
Career advice (1865)
Career pathing (44)
CAR-T (309)
CDC (61)
Celiac Disease (2)
Cell therapy (832)
Cervical cancer (41)
Clinical research (72808)
Collaboration (1995)
Company closure (5)
Compensation (1286)
Complete response letters (83)
COVID-19 (2823)
CRISPR (106)
C-suite (1014)
Cystic fibrosis (154)
Data (7124)
Decentralized trials (3)
Denatured (43)
Depression (160)
Dermatology (58)
Diabetes (571)
Diagnostics (6943)
Digital health (50)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (308)
Drug pricing (228)
Drug shortages (35)
Duchenne muscular dystrophy (273)
Earnings (93266)
Editorial (66)
Employer branding (21)
Employer resources (158)
Events (122580)
Executive appointments (1069)
FDA (20516)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1646)
Gene editing (224)
Generative AI (58)
Gene therapy (691)
GLP-1 (1136)
Government (4925)
Grass and pollen (7)
Guidances (398)
Healthcare (19254)
HIV (75)
Huntington's disease (53)
IgA nephropathy (95)
Immunology and inflammation (306)
Immuno-oncology (87)
Indications (158)
Infectious disease (3150)
Inflammatory bowel disease (211)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (278)
Interviews (345)
IPO (17096)
IRA (58)
Job creations (4179)
Job search strategy (1563)
JPM (71)
Kidney cancer (19)
Labor market (93)
Layoffs (609)
Leadership (42)
Legal (8582)
Liver cancer (100)
Longevity (29)
Lung cancer (733)
Lymphoma (412)
Machine learning (53)
Management (62)
Manufacturing (961)
MASH (188)
Medical device (13987)
Medtech (14064)
Mergers & acquisitions (21345)
Metabolic disorders (1530)
mRNA (187)
Multiple sclerosis (179)
NASH (21)
Neurodegenerative disease (403)
Neuropsychiatric disorders (108)
Neuroscience (3233)
Neurotech (1)
NextGen: Class of 2026 (6739)
Non-profit (4601)
Now hiring (73)
Obesity (748)
Opinion (323)
Ovarian cancer (187)
Pain (247)
Pancreatic cancer (256)
Parkinson's disease (348)
Partnered (34)
Patents (566)
Patient recruitment (602)
Peanut (64)
People (61814)
Pharmaceutical (95)
Pharmacy benefit managers (35)
Phase 1 (22707)
Phase 2 (31970)
Phase 3 (23935)
Pipeline (7193)
Policy (335)
Postmarket research (2687)
Preclinical (9570)
Press Release (68)
Prostate cancer (280)
Psychedelics (52)
Radiopharmaceuticals (313)
Rare diseases (1051)
Real estate (6418)
Recruiting (72)
Regulatory (26244)
Reports (54)
Research institute (2479)
Resumes & cover letters (374)
Rett syndrome (32)
RNA editing (19)
RSV (93)
Schizophrenia (173)
Series A (275)
Series B (205)
Service/supplier (14)
Sickle cell disease (110)
Special edition (28)
Spinal muscular atrophy (171)
Sponsored (46)
Startups (3846)
State (2)
Stomach cancer (20)
Supply chain (124)
Tariffs (100)
The Weekly (106)
Vaccines (1111)
Venture capital (105)
Weight loss (507)
Women's health (110)
Worklife (20)
Date
Today (153)
Last 7 days (724)
Last 30 days (2826)
Last 365 days (30866)
2026 (8164)
2025 (31086)
2024 (36140)
2023 (40929)
2022 (52114)
2021 (56674)
2020 (55108)
2019 (47821)
2018 (36139)
2017 (33569)
2016 (33169)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30871)
2010 (28889)
Location
Africa (830)
Alabama (90)
Alaska (7)
Arizona (340)
Arkansas (15)
Asia (43400)
Australia (6893)
California (12362)
Canada (3543)
China (1290)
Colorado (526)
Connecticut (525)
Delaware (373)
Europe (93652)
Florida (1883)
Georgia (394)
Hawaii (3)
Idaho (62)
Illinois (978)
India (82)
Indiana (573)
Iowa (22)
Japan (502)
Kansas (130)
Kentucky (44)
Louisiana (40)
Maine (73)
Maryland (1504)
Massachusetts (8870)
Michigan (350)
Minnesota (680)
Mississippi (6)
Missouri (138)
Montana (33)
Nebraska (29)
Nevada (139)
New Hampshire (82)
New Jersey (3317)
New Mexico (31)
New York (3262)
North Carolina (1623)
North Dakota (8)
Northern California (6097)
Ohio (371)
Oklahoma (23)
Oregon (47)
Pennsylvania (2507)
Puerto Rico (26)
Rhode Island (50)
South America (1200)
South Carolina (77)
South Dakota (1)
Southern California (4852)
Tennessee (202)
Texas (1950)
United States (44002)
Utah (370)
Vermont (1)
Virginia (309)
Washington D.C. (81)
Washington State (993)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
754,548 Results for "recludix pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments
March 16, 2026
·
6 min read
Press Releases
Recludix Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
·
1 min read
Press Releases
Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors
January 12, 2026
·
2 min read
Press Releases
Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology
January 8, 2026
·
7 min read
Press Releases
Recludix Pharma to Present at Two Investor Conferences in November 2025
November 4, 2025
·
1 min read
Press Releases
Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
December 17, 2025
·
3 min read
Press Releases
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
January 12, 2026
·
4 min read
Press Releases
Recludix Pharma to Present at the Stifel 2025 Virtual Immunology and Inflammation Forum
September 12, 2025
·
1 min read
Press Releases
Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific Officer
July 15, 2025
·
8 min read
Biotech Beach
Recludix Pharma to Participate in Two Investor Conferences in March 2024
Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, announced that members of Recludix’s management will host meetings at two investor conferences in March.
February 28, 2024
·
1 min read
1 of 75,455
Next
